Compare LITS & DRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITS | DRK |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 26.9M |
| IPO Year | 2003 | 2020 |
| Metric | LITS | DRK |
|---|---|---|
| Price | $1.18 | $1.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 729.9K | 165.4K |
| Earning Date | 11-16-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,181,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.92 |
| 52 Week High | $2.26 | $3.27 |
| Indicator | LITS | DRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 19.36 |
| Support Level | $1.12 | N/A |
| Resistance Level | $1.25 | $2.13 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 14.52 | 2.88 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.